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Abstract
Objectives The Phase I safety, biodistribution and inter-
nal radiation dosimetry study in adult healthy Japanese
males of flutemetamol (18F) injection, an in vivo b-amyloid
imaging agent, is reported and compared with previously
obtained Caucasian data.
Methods Whole-body PET scans of 6 healthy volunteers
(age 51.8–61.7 years) were acquired approximately 4 h
post-injection (administered activity 102–160 MBq). Ve-
nous blood sampling determined 18F activity concentra-
tions in whole blood and plasma and high-performance
liquid chromatography (HPLC) established the percentages
of parent [18F]flutemetamol and its metabolites. Voided
urine activity was recorded. The decay-corrected and nor-
malised 18F activity of 14 source organ regions as a func-
tion of time was entered into the OLINDA/EXM software
to calculate the internal radiation dosimetry and effective
dose of each subject following the MIRD schema. The
pharmacokinetics, biodistribution and dosimetry profiles
were compared to data obtained from a cohort of healthy
Caucasian adult volunteers from a previous Phase I study
of [18F]flutemetamol.
Results Flutemetamol (18F) injection was well tolerated.
The highest mean initial uptakes were measured in the liver
(15.2 %), lungs (10.2 %) and brain (6.6 %). The highest
mean radiation absorbed doses were received by the gall-
bladder wall (366 lGy/MBq), upper large intestine
(138 lGy/MBq) and small intestine (121 lGy/MBq). The
mean effective dose was 34.9 lSv/MBq. HPLC analysis
demonstrated that at 5-min post-injection about 75 % of
plasma 18F radioactivity was in the form of parent [18-
F]flutemetamol, reducing to 8 and 2 % at 25 and 90 min,
respectively, giving rise to less lipophilic 18F-labelled
metabolites. Comparisons with the Caucasian cohort
showed no differences that could be regarded as clinically
significant.
Conclusion The clinical safety of [18F]flutemetamol
demonstrated no differences of clinical significance in the
pharmacokinetics, biodistribution and internal radiation
dosimetry profiles between Caucasian and Japanese adults.
Keywords Amyloid imaging  [18F]Flutemetamol  PET 
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Introduction
b-Amyloid neuritic plaques are one of the characteristic
neuropathological hallmarks of Alzheimer disease (AD).
The capability of the in vivo imaging of this pathology
suggests the possibility to improve the accuracy of diag-
nosis at much earlier stages of disease and the ability to
measure the future potential efficacy arising from disease-
modifying therapies. Earlier imaging investigations using
the 11C-labelled thioflavin T derivative, known as Pitts-
burgh compound B ([11C]PiB), have been previously
conducted in clinically probable AD [1–3] and other de-
mentia types [4, 5]. The short 20-min physical half-life of
11C restricts the use of this radionuclide (and therefore the
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[11C]PiB compound) to facilities with an on-site cyclotron
where the transport time of 11C from the production site to
the imaging site is short. A natural focus therefore has
evolved towards the use of the radioisotope 18F, with its
longer physical half-life of 110 min, in the radiolabelling
of these amyloid-specific ligands.
[18F]Flutemetamol is a 18F-labelled thioflavin derivative
of the Pittsburgh B compound and has been under exten-
sive investigation of in vivo imaging of b-amyloid, mainly
in Caucasians [6–8]. [18F]Flutemetamol is structurally
identical to [11C]PiB apart from the inclusion of 18F at the
30 position. This paper describes a Phase 1, single-centre,
single-dose, open-label and non-randomised study de-
signed to be the first to evaluate the clinical safety,
biodistribution, pharmacokinetics and metabolism of 18F
and the internal radiation dosimetry resulting from an in-
travenous administration of flutemetamol (18F) injection in
a Japanese cohort of healthy adult volunteers. Clinical
safety, biodistribution and internal radiation dosimetry
assessments of [18F]flutemetamol have been performed
previously with a Caucasian cohort of healthy adult vol-
unteers [9] and these are compared with the results ob-
tained from this work. Because ethnicity may affect
transporters and metabolising enzymes that determine
pharmacokinetics and biodistribution [10, 11], it is essen-
tial to confirm inter-ethnic comparability for global use of
the PET drug.
Methods and materials
Unless specified otherwise, all numerical data are provided
as the mean ±1 standard deviation.
Subjects
This study was performed at the Institute of Biomedical
Research and Investigation (IBRI) in Kobe, Japan. Ap-
proval was received from the local Institutional Review
Board and the study was conducted in accordance with
Good Clinical Practice and the guidelines of the Interna-
tional Commission on Harmonisation. Six healthy adult
male Japanese volunteers with a mean age of
55.3 ± 3.6 years, a whole-body weight of 72.7 ± 15.7 kg
and a body-mass index of 24.4 ± 4.8 kg/m2 were recruit-
ed. The subject inclusion criteria included being of the
Japanese race, an age exceeding 50 years, the ability to
provide informed written consent, normal medical history
(including physical examination, electrocardiogram,
haematology and biochemistry), no evidence of cognitive
impairment by medical history and a Mini-Mental State
Examination score of 27 or greater.
Radiopharmaceutical preparation
[18F]Flutemetamol was synthesised on a FASTlab synthe-
siser model by the reaction of N-[4-(6-ethoxymethoxy-
benzothiazol-2-yl)-2-nitro-phenyl]-N-methylformamide
(AH111907) with [18F]fluoride and purified by solid phase
extraction followed by formulation into flutemetamol (18F)
injection. The investigational medical product was pre-
pared and handled according to Good Manufacturing
Practice at the PET drug manufacturing site, IBRI. The
manufacturing and analytical procedures, specifications
and associated documentation were prepared by GE
Healthcare and transferred to IBRI during a formal tech-
nology transfer process. The successful transfer was
assessed by the production and analysis of a minimum of
three technical batches. The measured radiochemical purity
was[99.9 % for every batch used for this study based on
the technical details which were defined in the testing
methods for this phase 1 study.
Administration
Flutemetamol (18F) injection was administered intra-
venously in an antecubital vein followed by a 5-ml saline
flush. The mean administered activity to the six subjects
was 130.2 ± 25.9 MBq (range 102.3–160.0 MBq) with an
injection volume of 1.5 ± 0.56 ml (range 1.0–2.5 ml). The
injected mass dose was 157 ± 54 ng (range 80–221 ng).
Safety data collection
Safety data were collected up to 24 h after injection and
included vital signs (blood pressure, respiratory rate, heart
rate and body temperature); cardiovascular, lung, abdomen
and neurological examinations; electrocardiogram; and
laboratory parameters including serum chemistry, haema-
tology, coagulation and urinalysis.
Venous blood samples were collected through an
indwelling catheter in an antecubital vein before and 30 m,
2.5 h, 4 h and 24 h after injection of drug product.
Pharmacokinetic measurement
Venous blood samples were taken at a nominal total of 10
time points (including a pre-injection sample) from 2 min
to 4 h post-injection (pi) for measurement of 18F activity
concentrations in whole blood and plasma. Three samples
(acquired at 5, 25 and 90 min pi) were further analysed
with high-performance liquid chromatography (HPLC) for
the presence of the parent [18F]flutemetamol and 18F-la-
belled metabolites over time.
The blood samples acquired at 5, 25 and 90 min pi were
collected in heparinised tubes and centrifuged at 5000 rpm,
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3500 G to obtain the plasma samples. Each plasma sample
was diluted 1:1 with liquid chromatography starting mobile
phase [acetonitrile/water (5/95 v/v) containing 0.05 M
sodium acetate (pH 5.5)] and 1.0 ml of this diluted sampled
was injected directly to the column. Deproteinization was
omitted to make sure the entire recovery of the plasma
radioactivity to obtain accurate % parent fraction value.
Radioactive components were analysed by using HPLC
system (LC-10AD, Shimadzu Co., Kyoto, Japan) with
NaI(Tl) radiation detector (US-2000, Universal Giken,
Odawara, Japan) to measure radioactive fractions, and the
elution was monitored by UV absorbance at 330 nm.
A Chromolith Performance RP-18e column (4.6 9
100 mm; Merck, Darmstadt, Germany) was used, and a
flow rate of 2.0 ml/min of acetonitrile/water (5/95 v/v)
containing 0.05 M sodium acetate (pH 5.5) was the initial
condition used. After 1.0 min of sample injection, the ratio
of acetonitrile/water was changed to 30/70 v/v for 3 min
and then changed to 95/5 v/v for 16 min and maintained for
the next 4 min. The columns were then washed with ace-
tonitrile/water (5/95 v/v) containing 0.05 M sodium acetate
(pH 5.5) for 4 min. A new column was used for each
subject and the HPLC analytical system was primed and
equilibrated at the beginning of the study day. All peaks
were identified and integrated manually and the areas-un-
der-the-curve for each peak was evaluated as a percentage
of the total peak area (i.e., the total 18F content in
circulation).
Urine was collected as voided up to the end of imaging
and the 18F activity content in each void measured.
Image acquisition and reconstruction
Whole-body emission images were acquired in 3D-mode
on a GE Discovery ST Elite Performance PET/CT platform
with a 15.7 cm axial field of view. Allowing for a 7-slice
overlap, the axial field of view was 13.4 cm per bed po-
sition. Prior to each emission imaging session, a whole-
body CT image was acquired for attenuation correction.
The axial extent of the emission images was from the head
to approximately mid-thigh in order to include the urinary
bladder contents within the image. The images were
composed of contiguous static positions that were acquired
at a number of bed positions with this number being de-
pendent upon the subject height.
Twelve serial three-dimensional whole-body PET im-
ages were acquired for each of the subjects beginning at
2 min pi and ending at about 4 h. The acquisition times per
bed position were increased from 30 to 60 s at 90 min pi
and to 120 s after 2 h pi so as to compensate for the
physical decay of 18F.
Emission images were reconstructed using ordered-
subset expectation minimisation with 8 iterations and 7
subsets with post-reconstruction smoothing using an
isotropic Gaussian filter (4.29 mm full-width half-max-
imum). Slice thickness was 3.27 mm and pixel size was
3.91 mm2.
Activity quantification
Image analysis was performed on a MIM workstation
(version 6.0). Volumes-of-interest (VOI) were drawn upon
the fused PET–CT data around organs and tissues that
demonstrated uptake of 18F. The VOI included, where
visible, brain, salivary glands, thyroid gland, lungs, heart,
liver, gall bladder contents, spleen, intestinal tract contents,
urinary bladder contents and remaining tissues. It was as-
sumed that the 18F activity in the unimaged lower ex-
tremities was equal to the difference between administered
activity and the sum of the imaged and excreted activities.
The separate 18F activities in heart wall and contents were
determined from the 18F activity measured within the VOI
over the heart and then by subtracting the contribution from
the heart contents estimated by the product of the measured
in vitro 18F concentration in whole blood and the reference
volume of the cardiac chamber blood [13].
The 18F activity data were decay-corrected to the time of
injection, normalised to the administered activity and then
integrated analytically as functions of time in order to yield
the normalised cumulated activities (NCAs) of the source
regions. The International Commission on Radiological
Protection (ICRP) dynamic gastrointestinal tract model
was used to calculate the NCAs of the contents of the
small, upper large and lower large intestines [14]. This was
done by fitting the decay-corrected and normalised activity
of the total intestinal contents as a function of time to an
asymptotic bi-exponential function and then using the co-
efficients of this fit to solve for the NCAs of the individual
intestinal compartments using the set of coupled differen-
tial equations and transit times provided in [12] and [14]. A
dynamic urinary bladder model was also used in order to
calculate the NCA of the urinary bladder contents [15]. As
recommended by the ICRP for adult subject, the urinary
bladder contents’ NCA was calculated for a 3.5-h voiding
interval [16].
Internal radiation dosimetry
The internal radiation dosimetry for each subject was
evaluated using the Medical Internal Radiation Dose
(MIRD) schema [17] with the Organ Level Internal Dose
Assessment/Exponential Modelling (OLINDA/EXM) soft-
ware [18] for the Cristy–Eckerman adult male (hermaph-
rodite) anthropomorphic phantom [19]. From the resulting
absorbed dose data for the 24 MIRD-specified target re-
gions, the effective dose was calculated separately for each
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subject using the tissue weighting factors provided in ICRP
Publication 60 [20]. In this calculation, the gonadal ab-
sorbed dose was taken to be the arithmetic average of the
absorbed doses to the testes and ovaries, the absorbed dose
to the thymus gland was used as a surrogate for the ab-
sorbed dose to the oesophagus and the absorbed dose to the
colon wall was taken to be equal to the mass-weighted sum
of the absorbed doses to the walls of the upper- and lower
large intestines.
Biodistribution and internal radiation dosimetry
of Caucasian cohort
Although the biodistribution and internal radiation
dosimetry of [18F]flutemetamol have been reported previ-
ously for a Caucasian cohort [9], the raw 18F activity data
from that study were re-analysed here following the same
methodologies as were used on the Japanese cohort (de-
scribed above) so as to enable an appropriate comparison
between the two cohorts. In particular, the ICRP gas-
trointestinal tract model was used on these data and the
urinary bladder contents’ NCA values were evaluated for a
3.5-h voiding interval rather than the 2-h interval reported
in [9]. The NCAs were evaluated analytically as described
above and the organ-absorbed doses and effective dose
calculated using the methods described previously.
Results
All 18F activities reported are decay-corrected to the time
of injection and expressed as percentages of the adminis-
tered activity. Differences in NCA and dose between the
two cohorts are assessed with a Student’s t test at a sig-
nificance of p\ 0.05.
Safety
One treatment-emergent adverse event was reported in the
form of diarrhoea during the course of the study and was
deemed unrelated to the administration of flutemetamol
(18F) injection. There was overall stability throughout the
follow-up period for all parameters, including clinical
laboratory variables, vital signs, and electrocardiograms. No
clinically important trends or safety signals were evident.
Biodistribution and pharmacokinetics
Figure 1 shows whole-body PET images of a representa-
tive subject at a number of time points following the ad-
ministration of flutemetamol (18F) injection. Figure 2
shows the mean time–activity curves for liver, brain, urine
and intestinal contents.
Excluding the remaining tissues category, the three
source regions with the highest mean initial 18F activity
uptake (defined as that measured at the initial imaging time
point) were liver at 15.2 % (range 13.4–19.5 %), lungs at
10.2 % (range 5.6–12.8 %) and brain at 6.6 % (range
4.4–8.3 %). Washout of 18F activity from brain was gen-
erally rapid and activity was reduced to half of its initial
uptake by about 1 h pi. Uptake in the liver rose to a mean
of 22 % approximately 50 min pi before falling to around
half this value 2 h later. Excretion of 18F activity was
distributed between the renal pathway with 32.6 ± 10.5 %
and the hepatobiliary pathway with 31.9 ± 16.9 %.
Table 1 summarises the NCA values determined for the
Japanese cohort of this work and for the Caucasian cohort
of Ref. [9].
Figure 3 presents the mean washout of activity from
whole blood and plasma. The plasma activity data from the
previous study on Caucasians (ALZ103) [6] are also shown
for comparison in Fig. 3. Figure 4 shows the HPLC traces
of 18F activity in plasma from a representative subject. The
signals of hydrophilic species exhibit a decreased retention
time. Figure 4a shows the radiochromatogram for a human
plasma sample spiked ex vivo with the parent [18-
F]flutemetamol and Fig. 4b–d shows radiochromatograms
obtained at 5, 25 and 90 min pi, respectively. When the
total radioactivity recovered in the HPLC effluent was
compared with the activity in each plasma sample applied
to the HPLC, the recovery rate (effluent/plasma) was
0.98 ± 0.16, indicating that all the activity in the plasma
samples was accounted for in the radio-HPLC analysis.
Figure 5 presents the mean 18F content in the form of
the [18F]flutemetamol parent and 18F-labelled metabolites
as a function of time following the administration of
flutemetamol (18F) injection. A large fraction of the ra-
dioactivity was in the form of the parent [18F]flutemetamol
at 5 min pi, which was rapidly metabolised into hy-
drophilic compounds at the later phases.
Internal radiation dosimetry
The absorbed doses per unit administered activity to the
MIRD-specified organs for the Japanese and Caucasian
cohorts are provided in Table 2.
In this work for the Japanese cohort, the three organs
with the largest absorbed doses were the gallbladder wall
(366 ± 72.2 lGy/MBq), upper large intestine (138 ±
71.4 lGy/MBq) and the small intestine (121 ±62.8 lGy/
MBq). The effective dose was calculated to be 34.9 ±
10.4 lSv/MBq.
For the Caucasian cohort, the three organs with the
largest absorbed doses were the gall bladder wall
(287 ± 24.6 lGy/MBq), urinary bladder wall (145 ±
49.9 lGy/MBq) and the wall of the upper large intestine
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(117 ± 36.0 lGy/MBq). The effective dose was calculated
to be 32.4 ± 6.5 lSv/MBq.
Discussion
Safety
The design of this study was to evaluate the biodistribution
of 18F and the internal radiation dosimetry associated with
[18F]flutemetamol in healthy adult Japanese volunteers as
well as the clinical safety of the drug product flutemetamol
(18F) injection. Flutemetamol (18F) injection was found to
be safe and well tolerated with one adverse event having
occurred in six subjects. This event was mild and was
judged to not be associated with the radiopharmaceutical.
Excretion of 18F in both the Japanese and Caucasian co-
horts was predominantly renal and the highest absorbed
doses were received by the urinary bladder wall, kidneys
and the liver.
Fig. 1 Collapsed coronal images of a representative subject following administration of flutemetamol (18F) injection acquired at times of (left to
right) 0.10, 0.55, 1.20, 2.57 and 3.94 h post-injection
Fig. 2 Mean decay-corrected
18F activity values in brain,
liver, urine and intestinal
contents for all six subjects as
functions of time following
administration of flutemetamol
(18F) Injection. Error bars are
drawn at ±1 standard deviation
and urine and intestinal contents
curves have been offset slightly
for clarity
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Pharmacokinetics and metabolism
This study demonstrates that the plasma time–activity
curve is similar to the Caucasian data acquired in the
previous study [6] (Fig. 3). HPLC analysis demonstrates
that [18F]flutemetamol is rapidly metabolised with only
8.3 ± 8 % present as the parent in circulation at 25 min pi
(Fig. 5). By that time 89.7 ± 8.5 % of 18F in the circula-
tion is represented by a metabolised species (region 2 in
Fig. 4b–d) more hydrophilic than the parent. These results
are not much different from the Caucasian data in [6] at
least during the initial 20–25 min pi, in which the fraction
of intact [18F]flutemetamol was 84.7 % (normal) and
77.5 % (AD) at 2 min but was decreased to 23.8 % (nor-
mal) and 27.0 % (AD) at 20 min and the activity turned
into hydrophilic metabolites. The parent fraction in the
later phase was lower than the Caucasian data, which is
difficult to interpret due to poor count statistics and the
difference in the equipment. With hindsight, the sensitivity
of radio-detector used in the HPLC analysis in the present
Table 1 Normalised cumulated
activities of flutemetamol (18F)
injection
Organ/tissue Normalised cumulated activities (MBq h/MBq)
Japanese (this work) Caucasiana
Mean Standard deviation Mean Standard deviation
Brain 0.059 0.016 0.061 0.006
Lungs 0.102 0.030 0.063 0.008
Heart
Wall 0.012 0.010 0.009 0.003
Contents 0.015 0.003 0.016 0.004
Spleen 0.009 0.010 0.008 0.003
Liver 0.367 0.048 0.399 0.051
Gall bladder contents 0.218 0.048 0.169 0.158
Intestinal contents
Small intestine 0.505 0.293 0.429 0.155
Upper large intestine 0.277 0.161 0.236 0.085
Lower large intestine 0.051 0.029 0.042 0.015
Kidneys 0.052 0.023 0.029 0.020
Urinary bladder wall (3.5-h voiding interval) 0.224 0.058 0.287 0.105
Remaining tissues 1.151 0.113 0.817 0.132
a Calculated from the data of [9]
Fig. 3 Decay-corrected 18F
activity concentration in whole
blood and plasma for all six
subjects as a function of time
following administration of
flutemetamol (18F) injection.
Data points, offset for clarity,
are mean values and uncertainty
error bars are ±1 standard
deviation. Plasma data from a
previous Caucasian study
(ALZ103) [6] are also shown
for comparison
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study was not sufficient for high-precision metabolite
analysis. As a result the tube volume was increased, re-
sulting in wide peaks shown in the charts of Fig. 4, which
might have masked small peaks close to the parent com-
pound. Within such methodological limitation of the study,
ethnic difference in pharmacokinetics and metabolism was
minimal.
A small peak representing a lipophilic labelled
metabolite was detected in the HPLC analysis, see ‘‘Region
4’’ in Fig. 4b, c. Although a lipophilic compound may enter
the brain, this would not influence the brain uptake mea-
sured with PET because the amount is small.
Because the plasma activity concentration and the
fraction of intact [18F]flutemetamol constitute the input
function to the brain, their similarity supports the funda-
mentals for the usefulness of brain PET imaging with
flutemetamol (18F) injection in the Japanese population to
the same extent as in the Caucasian population.
Comparison of biodistribution and internal
radiation dosimetry with Caucasian population
An earlier investigation of the biodistribution and internal
radiation dosimetry of flutemetamol (18F) injection in a
Caucasian population was described in [9]. Tables 1 and 2
Fig. 4 HPLC radiochromatograms for a plasma sample spiked
ex vivo with standard [18F]flutemetamol, and for the plasma obtained
from a representative subject at b 5, c 30 and d 90 min after
administration of flutemetamol (18F) injection. The vertical axis
shows ‘‘Radioactivity detector response (mV)’’ while the ‘‘Retention
time (min)’’ appears on the horizontal axis. Region 3 corresponds to
the [18F]flutemetamol parent in b, c and d as identified in a. Regions 1
and 2 correspond to metabolites that are more hydrophilic than the
parent of Region 3, and Region 4 represents a minor lipophilic
metabolite
Fig. 5 Mean areas-under-the-curve for radiochromatograms for
[18F]flutemetamol parent and 18F-labelled metabolities in plasma as
function of time following administration of flutemetamol (18F)
injection. Error bars are ±1 standard deviation. The fraction of the
parent compound ([18F]flutemetamol) in the plasma decreased from
75 % at 5 min to 8.3 % at 25 min with the majority of the plasma
activity bound to hydrophilic metabolites
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include our re-evaluations of the NCAs, organ-absorbed
doses and effective dose for that population. The dosimetry
data for the Caucasians presented here differ slightly from
those given by [9]. This is a consequence of having derived
the Caucasian results in the same manner as those of the
Japanese results using the procedures described in this
paper. In particular, the NCA for the urinary bladder con-
tents was calculated for a 2-h voiding interval in Ref. [9],
whereas in this paper the ICRP-recommended 3.5-h void-
ing interval was used. In Table 1, we see no significant
difference between the NCAs calculated for source regions
in the Japanese and Caucasian cohorts, with the exceptions
of the lungs and the remainder category. However, these
differences do not cause any issues from the standpoint of
clinical radiation exposure.
The organ-absorbed doses between the Japanese and
Caucasian cohorts are largely in agreement and, when
ranked in order of magnitude, it is only with the lungs in
tenth position that we begin to see any significant differ-
ence in absorbed dose. There is no statistical difference in
effective doses between the two the cohorts.
Conclusions
The first safety, biodistribution and internal radiation
dosimetry profiles in a Japanese healthy adult population
following the administration of flutemetamol (18F) injection
have been presented. It was demonstrated that flutemetamol
(18F) injection is safe and has an acceptable radiation
dosimetry profile. The radiopharmaceutical is rapidly
metabolised to form a species more hydrophilic than the
[18F]flutemetamol parent. A comparison of these data with
those obtained before for a Caucasian population has
demonstrated no differences of clinical significance between
these two populations for flutemetamol (18F) Injection.
Table 2 Organ and tissue-
absorbed doses normalised to
the administered activity for
flutemetamol (18F) injection
Organ/tissue Absorbed dose per unit administered activity (mGy/MBq)
Japanese (this work) Caucasiana
Mean Standard deviation Mean Standard deviation
Adrenal glands 1.51E-02 8.29E-04 1.29E-02 1.64E-03
Brain 1.11E-02 2.74E-03 1.13E-02 9.01E-04
Breasts 6.70E-03 3.28E-04 5.19E-03 6.17E-04
Gall bladder wall 3.66E-01 7.22E-02 2.87E-01 2.46E-01
Stomach 1.51E-02 2.55E-03 1.23E-02 1.00E-03
Intestinal walls
Small 1.21E-01 6.28E-02 1.02E-01 3.21E-02
Upper large 1.38E-01 7.14E-02 1.17E-01 3.60E-02
Lower large 4.90E-02 2.25E-02 4.17E-02 1.23E-02
Heart wall 1.73E-02 5.73E-03 1.45E-02 2.84E-03
Kidneys 4.42E-02 1.46E-02 3.12E-02 8.61E-03
Liver 5.55E-02 5.53E-03 5.72E-02 8.20E-03
Lungs 2.31E-02 5.01E-03 1.57E-02 1.53E-03
Muscle 1.05E-02 1.23E-03 8.69E-03 7.06E-04
Ovaries 2.86E-02 1.04E-02 2.49E-02 5.84E-03
Pancreas 1.81E-02 1.33E-03 1.50E-02 2.75E-03
Red marrow 1.18E-02 2.05E-03 1.34E-02 8.46E-04
Osteogenic cells 1.20E-02 9.22E-04 1.14E-02 8.17E-04
Skin 6.38E-03 4.55E-04 5.07E-03 4.14E-04
Spleen 1.75E-02 1.00E-02 1.46E-02 3.29E-03
Testes 8.64E-03 5.63E-04 7.52E-03 8.60E-04
Thymus gland 7.77E-03 3.93E-04 5.97E-03 7.46E-04
Thyroid gland 6.49E-03 5.55E-04 6.38E-03 1.56E-03
Urinary bladder wall 1.17E-01 2.75E-02 1.45E-01 4.99E-02
Uterus 2.74E-02 7.64E-03 2.54E-02 5.89E-03
ED (mSv/MBq) 3.49E-02 1.04E-02 3.24E-02 6.48E-03
a Calculated using the NCA data of Table 1
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